Clotprotect is developing CP101, a first-in-class small molecule direct plasmin inhibitor for intravenous administration. Their innovative approach aims to improve upon the current standard of care, tranexamic acid (TXA), by providing greater efficacy and thereby reducing bleeding and deaths, extending the treatment window beyond 3 hours from injury, and reducing hospital length of stay and decreased blood transfusions.

With significant commercial potential in the multi-billion dollar markets for trauma and surgical bleeding, CP101 could be a blockbuster product. Led by an experienced team, ClotProtect is well-positioned to address the unmet needs of TXA, with positive Phase II data. Their approach has the potential to revolutionize the treatment of severe bleeding.